Video: What I-SPY2 Data Stands Out for Breast Cancer? - Laura Ann Huppert, MD @laura_huppert @hoperugo @UCSF #ASCO22 #OncoTwitter

Video: What I-SPY2 Data Stands Out for Breast Cancer? - L...

1 month
10 Views
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Video: So the I-SPY2 trial is a neoadjuvant phase 2 study that enrolls patients with any type of breast cancer who have a tumor at least 2.5 centimeters in size and they're randomized to receive the control which is neoadjuvant Paclitaxel..Read Full Transcript Here

Laura Ann Huppert, MD, Hematology/Oncology Fellow, University of California San Francisco. In this video, she speaks about the ASCO 2022 Abstract - Molecular subtype to predict pathologic complete response in HER2-positive breast cancer in the I-SPY2 trial.

Synopsis:

The goal of this study is to advance personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images as well as tissue and blood samples) are predictors of treatment success.

Laura Ann Huppert, MD, Hematology/Oncology Fellow, University of California San Francisco. In this audio, she speaks about the ASCO 2022 Abstract - Molecular subtype to predict pathologic complete response in HER2-positive breast cancer in the I-SPY2 trial.

Overview:

The goal of this study is to advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are predictors of treatment success.

🔊Click for Audio Only